# **PATENT COOPERATION TREATY**

# **PCT**

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION as w	see Form PCT/ISA/220 vell as, where applicable, item 5 below.
X-16438		
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US2004/016623	17/06/2004	29/03/2004
Applicant		
ELI LILLY AND COMPANY		
This International Search Report has bee according to Article 18. A copy is being to	en prepared by this International Searching A ransmitted to the International Bureau.	Authority and is transmitted to the applicant
This International Search Report consists	s of a total of sheets.	
X It is also accompanied by	y a copy of each prior art document cited in t	his report.
	e international search was carried out on the eless otherwise indicated under this item.	basis of the international application in the
The international this Authority (Ru		nslation of the international application furnished to
b. X With regard to any nucle	otide and/or amino acid sequence disclos	sed in the international application, see Box No. I.
2. Certain claims were for	und unsearchable (See Box II).	
3. Unity of invention is lad	cking (see Box III).	
4. With regard to the title,		
X the text is approved as s	ubmitted by the applicant.	\$
the text has been establi	shed by this Authority to read as follows:	•
5. With regard to the abstract,		
=	ubmitted by the applicant.	
		cority as it appears in Box No. IV. The applicant earch report, submit comments to this Authority.
6. With regards to the drawings,		
a. the figure of the drawings to be	published with the abstract is Figure No	<del></del>
as suggested by	the applicant.	•
	is Authority, because the applicant failed to	•
	nis Authority, because this figure better chara	cterizes the invention.
b. X none of the figures is to t	be published with the abstract.	

Form PCT/ISA/210 (first sheet) (January 2004)

International application No.

PCT/US2004/016623

Вох	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed international search was carned out on the basis of
	a.	type of material  X a sequence listing table(s) related to the sequence listing
	b.	format of material  X in written format  X in computer readable form
	c.	ime of filing/furnishing         contained in the international application as filed         filed together with the international application in computer readable form         furnished subsequently to this Authority for the purpose of search
2.		In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished
3.	Additi	tional comments

International Application No PCT/US2004/016623

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER A61K38/12 A61P3/04		
According to	o International Patent Classification (IPC) or to both national classific	ation and IPC	
B. FIELDS	SEARCHED		
Minimum do IPC 7	ocumentation searched (classification system followed by classification A61K A61P	on symbols)	
Documentat	ion searched other than minimum documentation to the extent that s	uch documents are included in the fields searched	
	ata base consulted during the international search (name of data ba	•	
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages Re	levant to claim No
Y	√HASKELL-LUEVANO C ET AL:  "Characterization of melanocortin agonist peptide fragments at the central and peripheral melanocort receptors"  JOURNAL OF MEDICINAL CHEMISTRY, A CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 13, 2001, pages 2247 XP002970859  ISSN: 0022-2623 the whole document	NDP-MSH mouse in	-16
X Furth	ner documents are listed in the continuation of box C	Patent family members are listed in annex.	
"A" docume consider a filing different control of the control of t	are int which may throw doubts on priority claim(s) or its cited to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filling date but an the priority date claimed	"T" later document published after the international for priority date and not in conflict with the applic cited to understand the principle or theory under invention."  "X" document of particular relevance, the claimed in cannot be considered novel or carnot be considered novel or carnot be considered novel or the document is.  "Y" document of particular relevance, the claimed in cannot be considered to involve an inventive structure of the considered to involve an inventive structure of the combined with one or more other sments, such combination being obvious to a perior the art.  "8" document member of the same patent family	cation but infying the vention taken alone vention ep when the such docu-
	6 October 2004	Date of mailing of the international search report $10/11/2004$	
Name and m	nailing address of the ISA  European Patent Office, P B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx 31 651 epo nl,	Authorized officer	
	Fax: (+31-70) 340-3016	Fayos, C	

2

International Application No
PCT/US2004/016623

C (C===================================	Nicol DOCIMENTS CONSIDERED TO BE RELEVANT	PC1/US2004/016623
Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to clarm No
	onation of document, with manager, whose appropriate, of the following passages	Helevall to class No
Y	→PROIETTO J ET AL: "NOVEL ANTI-OBESITY DRUGS" EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 9, no. 6, June 2000 (2000-06), pages 1317-1326, XP001004696 ISSN: 1354-3784	1-26
X	page 1321, column 2, paragraph 3.2 - page 1322, column 1, paragraph 3.2.3	1-4, 10-12
Y	WO 00/33658 A (HOCHGESCHWENDER UTE ; BRENNAN MILES B (US); ELEANOR ROOSEVELT INST (US) 15 June 2000 (2000-06-15)	1-26
X	claims 1-124	1-4, 10-12
Y	WO 03/006604 A (MERCK & CO INC; BEDNAREK MARIA A (US)) 23 January 2003 (2003-01-23)	1-26
X	the whole document	1-4, 10-12
Y	HOLDER JERRY RYAN ET AL:  "Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors. 1. Modifications at the His position"  JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 13, 20 June 2002 (2002-06-20), pages 2801-2810, XP001183565 ISSN: 0022-2623 the whole document	1-26
Y	CHEUNG ADRIAN WAI-HING ET AL: "Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: Histidine substitution." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 1, 6 January 2003 (2003-01-06), pages 133-137, XP001183563 ISSN: 0960-894X	1-26
x	the whole document	1-4, 10-12
Y	US 2002/143141 A1 (YAGALOFF KEITH ALAN ET AL) 3 October 2002 (2002-10-03)	1-26
X	the whole document	1-4, 10-12
	-/	

International Application No
PCT/US2004/016623

		PCT/US2004/016623
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Υ	WO 00/58361 A (PROCTER & GAMBLE) 5 October 2000 (2000-10-05)	1-26
X	claims 1-15	1-5, 10-13
Y	WO 99/54358 A (QUADRANT HOLDINGS CAMBRIDGE , GISPEN WILLEM HENDRIK (NL); ADAN ROGER A) 28 October 1999 (1999-10-28)	1-26
(	the whole document	1-5, 10-13
9		

Information on patent family members

International Application No
PCT/US2004/016623

	atent document I in search report		Publication date		Patent family member(s)		Publication date
WO	0033658	A	15-06-2000	US_	6603058	R1	05-08-2003
	***************************************	•	10 00 2000	ΑŬ	3117600		26-06-2000
				CA	2353776		15-06-2000
				EP	1137340		04-10-2001
				JP	2003520015		02-07-2003
				WO	0033658		15-06-2000
				US	2003144174		31-07-2003
				US	6716810		06-04-2004
MO	03006604	Α	23-01-2003	CA	2453027		23-01-2003
				EP	1409521		21-04-2004
				MO	03006604		23-01-2003
				US	2004171793	Al 	02-09-2004
บร	2002143141	<b>A</b> 1	03-10-2002	AU	8402601		13-03-2002
				BR	0113637		25-02-2004
				CA	2420058		07-03-2002
				CN	1451017		22-10-2003
				CZ	20030584		13-08-2003
				WO	0218437		07-03-2002
				EP	1315750		04-06-2003
				HU	0303078	A2	29-12-2003
				JР	2004507558	T	11-03-2004
				NO	20030916	Α	27-02-2003
				NZ	523989	Α	27-08-2004
WO	0058361	A	05-10-2000	AU	763510	B2	24-07-2003
				ΑU	4017900	Α	16-10-2000
				BR	0009497	Α	15-01-2002
				CA	2368431	A1	05-10-2000
				CN	1345335	T	17-04-2002
				CZ	20013407	A3	13-02-2002
				ΕP	1165613	A1	02-01-2002
				HU	0202203	A2	28-10-2002
				ID	30262		15-11-2001
				JP	2002542159		10-12-2002
				MA	25403	A1	01-04-2002
				NO	20014568	Α	29-11-2001
				NZ	514141	Α	30-01-2004
				PL	350095	A1	04-11-2002
				RU	2213098		27-09-2003
				SK	13082001	A3	05-03-2002
				TR	200102765		21-05-2002
				WO	0058361		05-10-2000
				ÜS	6613874		02-09-2003
				ÜS	2004023859		05-02-2004
				ŽĀ	200107411		12-03-2002
 WO	9954358	Α	28-10-1999	ΑU	3615599	Α	08-11-1999